Change From Baseline in HbA1c to Week 24
| Group | Value (percentage of HbA1c) | Spread |
|---|---|---|
| Toujeo | -1.64 | 0.037 |
| Tresiba | -1.59 | 0.037 |
Trial · Interventional
CompletedPhase 4Results postedRegistry dataShort name BRIGHT
This trial does not test a peptide that PepBank tracks.
United States, Bulgaria, Croatia, Czechia, Denmark, France, Greece, Hungary, Israel, Italy, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
1 trial · 1 completed · 1 with posted results
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24. Secondary Objectives: Change From Baseline in HbA1c to Week 12 To assess the effects of the insulin Toujeo® in comparison with insulin Tresiba® at week 12 and week 24 on: * Change in Fasting plasma glucose (FPG); * Change in Fasting self-monitored plasma glucose (SMPG) and 4-point SMPG and 8-point SMPG profile; * Percentage of participants reaching HbA1c targets \<7% or ≤6.5%; * Percentage of participants reaching HbA1c targets \<7% or ≤6.5% without severe and/or confirmed hypoglycemia * Frequency of occurrence and diurnal distribution of hypoglycemia by American Diabetes Association (ADA) category of hypoglycemia. To assess the safety in each treatment group. To assess the treatment effects in each treatment group on Patient Reported Outcomes (PRO). Percentage of participants requiring rescue therapy.
Experimental
Toujeo
Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
Active comparator
Tresiba
Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
Outcomes the sponsor listed as primary.
Change From Baseline in HbA1c to Week 24
Time frame · Baseline, Week 24
Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Adjusted Least Square (LS) means and standard errors were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data, using all post-baseline HbA1c data available during the 24-week on-treatment period.
Change From Baseline in HbA1c to Week 12
Time frame · Baseline, Week 12
Change in HbA1c was calculated by subtracting baseline value from Week 12 value. Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 and Week 24
Time frame · Baseline, Week 12 and Week 24
Change in FPG was calculated by subtracting baseline value from Week 12 and Week 24 value. Adjusted LS means were obtained from MMRM including post baseline values during the 24-week on-treatment period.
Change From Baseline in Fasting Self-Monitoring Plasma Glucose (SMPG) to Week 12 and Week 24
Time frame · Baseline, Week 12 and Week 24
Fasting SMPG was measured by the participant before breakfast and before the administration of the glucose-lowering agents once a day during the study. Adjusted LS means were obtained from MMRM including post baseline values during the 24 week on treatment period.
Change From Baseline in 8 Point SMPG Profile to Week 12 and Week 24 Per Time Point
Time frame · Baseline, Week 12 and Week 24
8-point SMPG profiles were measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.
Change From Baseline in 4-point SMPG Profile to Week 12 and Week 24 Per Time Point
Time frame · Baseline, Week 12 and Week 24
4-point SMPG profiles were measured at the following 4 points: prebreakfast, prelunch, predinner and bedtime.
Change From Baseline in 24-hour Average 8-point SMPG Profile to Week 12 and Week 24
Time frame · Baseline, Week 12 and Week 24
The 8-point SMPG profile was measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Adjusted LS means were obtained from MMRM.
Change From Baseline in Variability of Fasting SMPG to Week 12 and Week 24
Time frame · Baseline, Week 12 and Week 24
Adjusted LS means were obtained from MMRM. Variability was assessed by the mean of coefficient of variation calculated over at least 3 SMPG measured during the 7 days preceding the given visit.
Change From Baseline in Variability of 24-Hour 8-Point SMPG Profiles at Week 12 and Week 24
Time frame · Baseline, Week 12 and Week 24
Adjusted LS means were obtained from MMRM.
Percentage of Participants Reaching Target HbA1c of < 7% and =<6.5% at Week 12 and Week 24
Time frame · Week 12, and Week 24
Only the post-baseline HbA1c measurements before rescue and during the 12 week and 24-week on-treatment period were considered in the analysis.
Percentage of Participants Reaching Target HbA1c <7% and =<6.5% at Week 12 and Week 24 Without Severe and/or Confirmed Hypoglycemia (70 mg/dL) Event
Time frame · Week 12, and Week 24
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed by plasma glucose =\<3.9 mmol/L (=\<70 mg/dL).
Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period
Time frame · Baseline to Week 24
Percentage of participants With Sulphonylurea or Meglitinide dose reduction/ discontinuation due to Hypoglycemia during 24 Week treatment period were reported. Only participants with Sulphonylurea or meglitinides at Screening as per actual strata were taken into account in this analysis.
Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period
Time frame · Baseline to Week 24
Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. Threshold values at Week 12: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.
Change From Baseline in Basal Insulin Dose (U/kg Body Weight) to Week 12 and Week 24
Time frame · Baseline, Week 12 and Week 24
Only the insulin dose measurements performed before initiation of rescue therapy and during the on-treatment period were considered in the analysis.
Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) by Study Period
Time frame · Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks (24W)). Percentage of participants with at least one hypoglycemia (hypo) event at any time of the day were reported.
Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal) by Study Period
Time frame · Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycaemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks).
Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) Event Rate Per Participant Year During Study Period
Time frame · Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L).
Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period
Time frame · Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time).
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (percentage of HbA1c) | Spread |
|---|---|---|
| Toujeo | -1.64 | 0.037 |
| Tresiba | -1.59 | 0.037 |
| Group | Value (percentage of HbA1c) | Spread |
|---|---|---|
| Toujeo | -1.37 | 0.036 |
| Tresiba | -1.39 | 0.036 |
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Toujeo | -3.64 | 0.099 |
| Tresiba | -3.89 | 0.100 |
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Toujeo | -3.26 | 0.067 |
| Tresiba | -3.25 | 0.067 |
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Toujeo | -2.77 | 3.16 |
| Tresiba | -2.28 | 3.49 |
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Toujeo | -3.41 | 2.75 |
| Tresiba | -2.97 | 2.62 |
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Toujeo | -2.57 | 0.092 |
| Tresiba | -2.50 | 0.093 |
| Group | Value (percentage of mean variability) | Spread |
|---|---|---|
| Toujeo | 2.38 | 0.418 |
| Tresiba | 2.62 | 0.416 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| ToujeoToujeo® (Insulin glargine, 300 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment. | 1 / 462 | 21 / 462 | 56 / 462 |
| TresibaTresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment. | 0 / 462 | 20 / 462 | 58 / 462 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
No study cites this trial.
References listed at the registry that are not in PepBank. They link to PubMed.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated